Pramlintide
- Generic Name
- Pramlintide
- Brand Names
- Symlin
- Drug Type
- Small Molecule
- Chemical Formula
- C171H267N51O53S2
- CAS Number
- 151126-32-8
- Unique Ingredient Identifier
- D3FM8FA78T
Overview
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Background
Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Indication
用于1型和2型糖尿病的辅助治疗。
Associated Conditions
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Clinical Trials
FDA Approved Products
SymlinPen
Manufacturer:AstraZeneca Pharmaceuticals LP
Route:SUBCUTANEOUS
Strength:1000 ug in 1 mL
Approved: 2019/12/18
NDC:0310-6615
SymlinPen
Manufacturer:AstraZeneca Pharmaceuticals LP
Route:SUBCUTANEOUS
Strength:1000 ug in 1 mL
Approved: 2019/12/18
NDC:0310-6627
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath